Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Completed · Phase 2 · Has a placebo group
Conditions studied: Heart Failure
In brief
Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that has no proven effective treatment. This study will assess the effects of nebulized inhaled nitrite administration on resting and exercise hemodynamics in patients with HFpEF referred to the catheterization lab.
Key facts
- Study ID
- NCT02262078
- Run by
- Mayo Clinic
- People needed
- 26
- Starts
- 2014-10-01
- Expected to finish
- 2015-12-01
- Last updated by the study team
- 2017-08-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Heart Failure with preserved Ejection Fraction (HFpEF) is defined by clinical symptoms of dyspnea and fatigue
- Normal left ventricular ejection fraction (>/=50%)
- And elevated Left Ventricular (LV) filling pressure at cardiac catheterization (defined as resting Pulmonary Capillary Wedge Pressure (PCWP)>15 mmHg and/or PCWP >/=25 mmHg during exercise).
You may not qualify if…
- Systolic Blood Pressure <120 mmHg (during catheterization)
- Prior nitrate therapy (within previous 2 weeks)
- Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
- Other "non-HFpEF" specific causes of heart failure such as significant valvular disease (>moderate left-sided regurgitation, >mild stenosis)
- Severe pulmonary disease
- Unstable coronary disease or coronary spasm
- Primary renal or hepatic disease (end stage renal failure/on dialysis or clinical diagnosis of hepatitis or hepatic cirrhosis)
- Constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies
- Pregnant
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.